Logo image of SOPH

SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis

USA - NASDAQ:SOPH - CH1125843347 - Common Stock

3.86 USD
-0.07 (-1.78%)
Last: 9/23/2025, 10:18:27 AM
Fundamental Rating

2

Overall SOPH gets a fundamental rating of 2 out of 10. We evaluated SOPH against 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of SOPH have multiple concerns. SOPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SOPH has reported negative net income.
In the past year SOPH has reported a negative cash flow from operations.
In the past 5 years SOPH always reported negative net income.
In the past 5 years SOPH always reported negative operating cash flow.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SOPH's Return On Assets of -45.10% is on the low side compared to the rest of the industry. SOPH is outperformed by 71.43% of its industry peers.
The Return On Equity of SOPH (-77.29%) is worse than 68.57% of its industry peers.
Industry RankSector Rank
ROA -45.1%
ROE -77.29%
ROIC N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SOPH has a better Gross Margin (68.09%) than 71.43% of its industry peers.
SOPH's Gross Margin has been stable in the last couple of years.
SOPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SOPH has more shares outstanding
SOPH has more shares outstanding than it did 5 years ago.
SOPH has a worse debt/assets ratio than last year.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SOPH has an Altman-Z score of -1.59. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
SOPH's Altman-Z score of -1.59 is on the low side compared to the rest of the industry. SOPH is outperformed by 65.71% of its industry peers.
SOPH has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.33, SOPH is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -1.59
ROIC/WACCN/A
WACC5.07%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.11 indicates that SOPH has no problem at all paying its short term obligations.
The Current ratio of SOPH (3.11) is better than 68.57% of its industry peers.
A Quick Ratio of 2.94 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a Quick ratio of 2.94. This is in the better half of the industry: SOPH outperforms 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 2.94
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

SOPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.84%.
SOPH shows a small growth in Revenue. In the last year, the Revenue has grown by 7.31%.
The Revenue has been growing by 20.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.48%
Revenue 1Y (TTM)7.31%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%15.91%

3.2 Future

The Earnings Per Share is expected to grow by 10.68% on average over the next years. This is quite good.
Based on estimates for the next years, SOPH will show a very strong growth in Revenue. The Revenue will grow by 25.48% on average per year.
EPS Next Y-15.69%
EPS Next 2Y3.89%
EPS Next 3Y10.68%
EPS Next 5YN/A
Revenue Next Year14.34%
Revenue Next 2Y16.53%
Revenue Next 3Y18.08%
Revenue Next 5Y25.48%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SOPH. In the last year negative earnings were reported.
Also next year SOPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y10.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SOPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOPHIA GENETICS SA

NASDAQ:SOPH (9/23/2025, 10:18:27 AM)

3.86

-0.07 (-1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-13 2025-10-13/amc
Inst Owners48.35%
Inst Owner Change-29.1%
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap260.86M
Analysts85.45
Price Target7.14 (84.97%)
Short Float %0.07%
Short Ratio0.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.83%
Min EPS beat(2)-2.99%
Max EPS beat(2)-0.67%
EPS beat(4)1
Avg EPS beat(4)-0.71%
Min EPS beat(4)-19.35%
Max EPS beat(4)20.18%
EPS beat(8)3
Avg EPS beat(8)2.28%
EPS beat(12)7
Avg EPS beat(12)8.94%
EPS beat(16)10
Avg EPS beat(16)10.55%
Revenue beat(2)1
Avg Revenue beat(2)0.55%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)2.98%
Revenue beat(4)1
Avg Revenue beat(4)-2.94%
Min Revenue beat(4)-10.93%
Max Revenue beat(4)2.98%
Revenue beat(8)2
Avg Revenue beat(8)-2.64%
Revenue beat(12)3
Avg Revenue beat(12)-2.12%
Revenue beat(16)5
Avg Revenue beat(16)-0.8%
PT rev (1m)-8.7%
PT rev (3m)2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.88
P/FCF N/A
P/OCF N/A
P/B 3.05
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.99
BVpS1.27
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.1%
ROE -77.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.09%
FCFM N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.27%
Cap/Sales 11.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 2.94
Altman-Z -1.59
F-Score3
WACC5.07%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.48%
EPS Next Y-15.69%
EPS Next 2Y3.89%
EPS Next 3Y10.68%
EPS Next 5YN/A
Revenue 1Y (TTM)7.31%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%15.91%
Revenue Next Year14.34%
Revenue Next 2Y16.53%
Revenue Next 3Y18.08%
Revenue Next 5Y25.48%
EBIT growth 1Y14.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.97%
EBIT Next 3Y21.86%
EBIT Next 5Y23.92%
FCF growth 1Y38.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.12%
OCF growth 3YN/A
OCF growth 5YN/A